Virological Outcomes After Switching to Abacavir/Lamivudine/Dolutegravir Combined with Adherence Support in People Living with HIV with Poor Adherence: A Phase IV, Multicentre Randomized Prospective Open Label Study (TriiADD-CTN 286).
Marina B KleinJim YoungDavid Ortiz-ParedesShouao WangSharon WalmsleyAlexander WongValérie Martel-LaferrièreNeora PickBrian ConwayJonathan AngelJean-Guy BarilChris FraserBertrand LebouchéDarrell Hoi-San TanRoger SandreSylvie TrottierHansi PeirisJayamarx JayaramanJoel Singernull nullPublished in: Patient preference and adherence (2022)
Results of our trial are consistent with a slight improvement in viral suppression in a vulnerable population when a single tablet regimen is combined with patient-level adherence support. Beyond treatment simplicity and tolerability, tailored interventions addressing stigma and social determinants of health are still needed. The numerous challenges we encountered illustrate how randomised trials may not be the best approach for assessing adherence interventions in vulnerable populations.
Keyphrases
- open label
- phase iii
- phase ii
- clinical trial
- double blind
- study protocol
- placebo controlled
- phase ii study
- hiv infected patients
- physical activity
- healthcare
- glycemic control
- randomized controlled trial
- case report
- public health
- hiv infected
- type diabetes
- metabolic syndrome
- smoking cessation
- squamous cell carcinoma
- risk assessment
- hiv aids
- radiation therapy
- weight loss
- replacement therapy
- insulin resistance
- adipose tissue
- skeletal muscle
- human health